Poster
AACR 2024 Poster
Mutational signatures in PDXs for improved understanding of drug response and companion biomarkers identification
Summary
Genomic DNA editing, influenced by DNA repair mechanisms and external factors like carcinogens or therapies, plays a key role in cancer development. Recent analyses have identified mutational signatures that highlight DNA repair deficiencies or environmental exposures. This poster highlights our TumorGraft platform, which features 1,500 patient-derived xenografts from over 50 cancer types. Each model is molecularly characterized using transcriptomics, proteomics, and genomic variation, offering valuable insights into cancer biology and mutational signatures providing a comprehensive preclinical platform for evaluating new drugs.
PDXs (Patient-Derived Xenografts) retain mutational signatures that correlate with tumor etiology and clinical features of patients.
PDXs were also effective in identifying new mutational signatures for model selection and biomarker discovery.
Integrating mutational signature data into the PPMO workflow could significantly aid in identifying companion biomarkers and developing unique molecular profiles to enhance personalized medicine approaches.